In the published article, there was an error in Affiliation 13. Instead of “Sanofi R&D, Integrated Drug Discovery, Medicinal Chemistry, Therapeutic Area Immunology & Inflammation, Vitry-sur-Seine, France”, it should be “Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France”.
In the published article, there was an error in the Author list, and authors Zhaoning Zhu, Jag Heer, and Laurent Schio were erroneously excluded. The corrected author list appears below.
Alexander Vugler1, James O’Connell2*, Mai Anh Nguyen3, Dietmar Weitz4, Thomas Leeuw5, Elizabeth Hickford6, Alexander Verbitsky7*, Xiaoyou Ying7, Markus Rehberg8, Bruce Carrington2, Mark Merriman1, Andrew Moss9, Jean-Marie Nicholas10, Phil Stanley1, Sara Wright11, Tim Bourne12, Yann Foricher13, Zhaoning Zhu14, Daniel Brookings14, Helen Horsley14, Jag Heer14, Laurent Schio13, Matthias Herrmann5, Srinivas Rao7, Markus Kohlmann15 and Peter Florian5†
In the published article, there was an error in the Conflict of Interest statement. The individual involvement of Zhaoning Zhu, Jag Heer, and Laurent Schio was omitted. The correct Conflict of Interest statement appears below.
In the published article, there was an error in the Author contributions statement. The individual contributions of Zhaoning Zhu, Jag Heer, and Laurent Schio were omitted. The correct Author contributions statement appears below.
Statements
Author contributions
MK, JO’C, AV, and PF wrote the first draft and compiled the final manuscript. The key data and overall concept of the manuscript was led by AV and PF who were the pharmacology leads on the oral TNF inhibitor program between UCB and Sanofi. In vitro assay data were summarized and provided by EH, BC, MM, and AM together with TL who finally reviewed the data. MN, DW, J-MN, and MR contributed with expert views on PKDM, DMPK and QSP modelling, respectively. The micro-CT study of the CIA model samples was performed by AVe and XY. SR provided pathology view and expert input on some primary CT images. PS conducted the statistical analysis of the CIA in vivo model data and provided the graphical representation. ZZ, LS, DB, HH, JH, and YF were instrumental in the discovery and synthesis of the compound. ZZ and LS were the chemistry leads between UCB and Sanofi. SW, TB and MH were the global project leads for the oral TNF inhibitor program and revised the final version prior to submission.
Conflict of interest
AV, JO'C, MN, DW, TL, EH, AVe, XY, MR, BC, MM, AM, J-MN, PS, SW, YF, ZZ, DB, HH, JH, LS, MH, SR, MK, and PF are either employees of UCB Pharma or Sanofi and may hold stock of the respective organizations. PF was employed by Sanofi-Aventis Deutschland GmbH at the time the work of the manuscript was conducted. He is now an employee of Boehringer Ingelheim Vetmedica GmbH. TB was employed by Milvuswood Consultancy.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
TNF, rheumatoid arthritis, small molecule, TNF trimer, immunogenicity
Citation
Vugler A, O’connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicolas J-M, Stanley P, Wright S, Bourne T, Foricher Y, Zhu Z, Brookings D, Horsley H, Heer J, Schio L, Herrmann M, Rao S, Kohlmann M and Florian P (2024) Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Front. Pharmacol. 15:1479557. doi: 10.3389/fphar.2024.1479557
Received
12 August 2024
Accepted
26 September 2024
Published
16 October 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
15 - 2024
Updates
Copyright
© 2024 Vugler, O’connell, Nguyen, Weitz, Leeuw, Hickford, Verbitsky, Ying, Rehberg, Carrington, Merriman, Moss, Nicolas, Stanley, Wright, Bourne, Foricher, Zhu, Brookings, Horsley, Heer, Schio, Herrmann, Rao, Kohlmann and Florian.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alexander Vugler, alexander.vugler@ucb.com; James O’connell, jimioconnell@virginmedia.com
† Present address: Peter Florian, Boehringer Ingelheim Vetmedica GmbH, Global AH Research, Ingelheim am Rhein, Germany
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.